![logo](/logos/JANX.webp)
Janux Therapeutics, Inc.
NASDAQ:JANX
41.26 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Janux Therapeutics, Inc. |
Symbool | JANX |
Munteenheid | USD |
Prijs | 41.26 |
Beurswaarde | 2,152,307,270 |
Dividendpercentage | 0% |
52-weken bereik | 5.65 - 65.6 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. David Alan Campbell Ph.D. |
Website | https://www.januxrx.com |
An error occurred while fetching data.
Over Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)